CORAL SPRINGS, FL--(Marketwire - 09/27/10) - Nutra Pharma Corporation (OTC.BB:NPHC - News), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), Multiple Sclerosis (MS) and Pain, introduced today Nyloxin for Pets, a new pain reliever aimed at treating moderate to severe chronic pain in companion animals.

ADVERTISEMENT

"Companion animals play an important role in our homes and communities and are, oftentimes, considered extended members of the family," commented Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. "As pet owners, many of us will seek out new, innovative and safe treatments for our pets as they become older and less agile. I believe that both pet owners and veterinarians will prefer the safety and efficacy profile offered by Nyloxin for Pets over alternative pain relievers that contain opiates, acetaminophen and other potentially harmful pharmaceutical ingredients," he added.

According to a 2009 survey conducted by the American Pet Products Association, 93.6 million cats and 77.5 million dogs were owned as pets in the United States. Additionally, the same report published sales for pet supplies, including over-the-counter medicines, totaling $10.48 billion for the same period.

"Nyloxin for Pets offers the opportunity to expand our Nyloxin brand into the large and growing animal health and wellness industry," explained David Isserman, Chief Marketing Officer of Nutra Pharma Corporation. "As we move forward with this launch, we plan to align ourselves with qualified pet care distributors that can provide the necessary support for national market penetration," he concluded.

Nyloxin for Pets will be available in an everyday strength sold through retailers and in an extra strength sold only through veterinarian offices. Additionally, Nyloxin for Pets will be specifically formulated to treat moderate to severe chronic pain from hip dysplasia, arthritis, and joint inflammation.